Duchenne approval exposes FDA rift over Sarepta gene therapy

Peter Marks’ decision to override the objections of agency staff and broaden use of Elevidys could have a “lasting impact” on gene therapy as well as the FDA, one analyst wrote.

Ben Fidler Member since June 22, 2024

Loading + Follow Following